X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with VENUS REMEDIES - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs VENUS REMEDIES - Comparison Results

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES VENUS REMEDIES ALKEM LABORATORIES/
VENUS REMEDIES
 
P/E (TTM) x - -696.7 - View Chart
P/BV x 7.4 0.2 3,651.9% View Chart
Dividend Yield % 0.6 0.0 -  

Financials

 ALKEM LABORATORIES   VENUS REMEDIES
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
VENUS REMEDIES
Mar-16
ALKEM LABORATORIES/
VENUS REMEDIES
5-Yr Chart
Click to enlarge
High Rs1,589218 728.9%   
Low Rs1,23282 1,500.6%   
Sales per share (Unadj.) Rs417.5365.6 114.2%  
Earnings per share (Unadj.) Rs56.31.5 3,788.3%  
Cash flow per share (Unadj.) Rs64.737.9 170.6%  
Dividends per share (Unadj.) Rs12.700-  
Dividend yield (eoy) %0.90-  
Book value per share (Unadj.) Rs292.9382.5 76.6%  
Shares outstanding (eoy) m119.5711.44 1,045.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.40.4 823.3%   
Avg P/E ratio x25.1101.0 24.8%  
P/CF ratio (eoy) x21.84.0 550.9%  
Price / Book Value ratio x4.80.4 1,227.5%  
Dividend payout %22.60-   
Avg Mkt Cap Rs m168,6531,717 9,825.0%   
No. of employees `000NA1.0 0.0%   
Total wages/salary Rs m9,171324 2,827.2%   
Avg. sales/employee Rs ThNM4,100.7-  
Avg. wages/employee Rs ThNM318.0-  
Avg. net profit/employee Rs ThNM16.7-  
INCOME DATA
Net Sales Rs m49,9154,183 1,193.4%  
Other income Rs m1,64520 8,184.6%   
Total revenues Rs m51,5614,203 1,226.8%   
Gross profit Rs m8,482812 1,045.1%  
Depreciation Rs m1,006417 241.3%   
Interest Rs m671380 176.6%   
Profit before tax Rs m8,45135 24,076.9%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,60618 8,872.9%   
Profit after tax Rs m6,73117 39,595.3%  
Gross profit margin %17.019.4 87.6%  
Effective tax rate %19.051.6 36.9%   
Net profit margin %13.50.4 3,317.9%  
BALANCE SHEET DATA
Current assets Rs m27,0622,771 976.7%   
Current liabilities Rs m15,3241,931 793.4%   
Net working cap to sales %23.520.1 117.2%  
Current ratio x1.81.4 123.1%  
Inventory Days Days67125 53.2%  
Debtors Days Days4154 76.8%  
Net fixed assets Rs m12,6105,328 236.6%   
Share capital Rs m239114 209.0%   
"Free" reserves Rs m34,4904,177 825.7%   
Net worth Rs m35,0274,376 800.4%   
Long term debt Rs m1,2121,911 63.4%   
Total assets Rs m54,3878,428 645.3%  
Interest coverage x13.61.1 1,245.1%   
Debt to equity ratio x00.4 7.9%  
Sales to assets ratio x0.90.5 184.9%   
Return on assets %13.64.7 289.1%  
Return on equity %19.20.4 4,947.1%  
Return on capital %24.96.6 376.6%  
Exports to sales %12.90-   
Imports to sales %3.120.5 15.0%   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540858 179.5%   
Fx inflow Rs m6,5630-   
Fx outflow Rs m3,012858 350.9%   
Net fx Rs m3,552-858 -413.8%   
CASH FLOW
From Operations Rs m7,259469 1,548.3%  
From Investments Rs m1,86429 6,384.2%  
From Financial Activity Rs m-9,273-464 2,000.6%  
Net Cashflow Rs m-15035 -434.8%  

Share Holding

Indian Promoters % 66.9 32.9 203.7%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 33.1 0.2 18,388.9%  
FIIs % 0.0 0.6 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 66.4 -  
Shareholders   68,381 20,121 339.8%  
Pledged promoter(s) holding % 0.0 36.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   FRESENIUS KABI ONCO.  DIVIS LABORATORIES  FULFORD INDIA  ALEMBIC PHARMA  ELDER PHARMA  

Compare ALKEM LABORATORIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Strong; Metal, Pharma Stocks Lead Gains(01:30 pm)

After opening the day in green, share markets in India have continued the momentum and are presently trading above the dotted line.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Feb 23, 2018 02:13 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - GSK PHARMA COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS